PipelineReview.com10h
Zai Lab Announces Strategic Partnership with MediLink Therapeutics to Develop a Novel LRRC15 Antibody-Drug Conjugate
SHANGHAI & SUZHOU, China & CAMBRIDGE, MA, USA I January 09, 2025 I Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a new strategic ...
PipelineReview.com10h
Sciwind Biosciences Announces Global Licensing and Collaboration Agreement for Metabolic Disease Portfolio
HANGZHOU, China I January 10, 2025 I Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative ...
PipelineReview.com23h
Climb Bio Expands Pipeline Through an Exclusive License to Develop and Commercialize an Antibody Targeting the APRIL Pathway for IgA Nephropathy
New Program is a Highly Potent, Fc-engineered anti-APRIL Monoclonal Antibody Specifically Designed to Address Patient Needs ...
PipelineReview.com1d
Genascence Announces Six-Month Results from Phase 1b DONATELLO Trial Indicating GNSC-001 Was Safe and Well Tolerated Across Multiple Dosing Arms
Mean IL-1Ra expression reached and maintained target levels in synovial fluid throughout six-month follow-up period ...